Search Medical Condition
Please enter condition
Please choose location from dropdown
 

La Madeleine, France Clinical Trials

A listing of La Madeleine, France clinical trials actively recruiting patients volunteers.

RESULTS

Found (387) clinical trials

Study to Compare the Efficacy of Pristinamycin (Pyostacine ) Versus Amoxicillin in the Treatment of Acute Community Acquired Pneumonia

The total study duration for each patient is 1 month with a treatment period of 7 to 9 days and a follow-up period of 21 to 23 days.

Phase

0.28 miles

Learn More »

French Lumbar Total Disk Replacement Observational Study

Secondary objectives: The secondary objectives are: Describe the reasons for re-interventions operated floor and / or (x) level (s) adjacent (s) Describe the evolution of the function with the functional Oswestry score Describe the evolution of lumbar radicular pain by visual analog scale (VAS) Describe the evolution of the quality ...

Phase N/A

1.46 miles

Learn More »

Clinical and Radiological Outcomes of Medacta Shoulder System

This is a post-marketing surveillance on Medacta Shoulder System

Phase N/A

1.46 miles

Learn More »

Evaluation of the DIABEO System in Poorly Controlled DM1 or DM2 Patients Treated With a Basal-bolus Insulin Regimen

The aim of the TELESAGE study is to demonstrate the superiority of follow up with the DIABEO system (software alone) versus usual follow up in terms of improvement in HbA1c after 1 year in DM1 or DM2 patients treated with a basal-bolus insulin regimen. the superiority of follow up with ...

Phase N/A

1.5 miles

Learn More »

Hypofractionated vs Standard Radiotherapy in Breast Cancer With an Indication for Regional Lymph Node Irradiation About Lymphedema Occurrence

The standard treatment of localized breast cancers consists of surgical removal of the tumor at the breast or removal of the entire breast and lymph nodes (sentinel lymph node and / or axillary dissection) with or without chemotherapy followed by radiotherapy on the breast or thoracic wall and the lymph ...

Phase N/A

1.5 miles

Learn More »

Darbepoetin Alpha in Myelodysplastic Syndromes (MDS)

Inclusion of MDS with IPSS low or int-1 and hemoglobin < 10/dL. Study drug: Darbepoetin alfa (Aranesp) 500 microg every two weeks subcutaneously during 12 weeks, combined to filgrastim 300 microg twice weekly for an additional 12 weeks in non responders. Response will be evaluated at 12 weeks. Patients with ...

Phase

1.91 miles

Learn More »

Nutritional Metabolic and Respiratory Status in Cystic Fibrosis

Diabetes is a important complication of cystic fibrosis (CF). The improved life expectancy of patients with cystic fibrosis, as a result of advances in medical therapy, has resulted in an increasing prevalence of cystic fibrosis-related diabetes (CFRD). CFRD is associated with accelerated pulmonary decline and increased mortality. Pulmonary effects are ...

Phase N/A

1.91 miles

Learn More »

Sorafenib in Treating Patients With Angiosarcoma That is Locally Advanced Metastatic or Unable to Be Removed by Surgery

OBJECTIVES: Primary - Determine the rate of non-progression at 9 months in patients with unresectable, locally advanced, or metastatic angiosarcoma treated with sorafenib tosylate. Secondary - Determine the rate of non-progression at 60, 120, and 180 days. - Determine the median time to progression. - Determine overall survival. - Determine ...

Phase

1.91 miles

Learn More »

Letrozole Anastrozole Exemestane or Tamoxifen Citrate in Treating Postmenopausal Women With Breast Cancer

OBJECTIVES: Primary - To evaluate verbal episodic memory in patients with breast cancer after 6 months of treatment with aromatase inhibitors (AI) vs tamoxifen citrate. Secondary - To evaluate cognitive functions of these patients at month 6 and 12 of treatment. - To evaluate the psychological and social impact on ...

Phase

1.91 miles

Learn More »

Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell Cancer

OBJECTIVES: Primary - To determine the objective tumor response rate in patients with locally advanced or metastatic papillary renal cell carcinoma treated with sunitinib malate. Secondary - To evaluate the safety of this drug in these patients. - To determine time-to-event variables of overall survival, time to disease progression, time ...

Phase

1.91 miles

Learn More »